Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
Limited progress has been made in identifying novel targets that may be therapeutic for
Osteosarcoma(OS) and there remains an urgent need for the development of new agents that are
effective in improving survival. From this perspective, repurposing already proven targets in
other tumors may offer new opportunities for OS in children and young adults. Anecdotal
evidence of anti-GD2 therapy exists in OS from prior Phase 1 trials that included patients
with OS.